Pharma Mar SA (ES:PHM) has released an update.
PharmaMar SA has reported an 8% increase in total revenue to €126.5 million as of September 30, 2024, with net profit rising to €7.4 million. The company’s earnings have been bolstered by a 10% growth in royalties, particularly from its partnership with Jazz Pharmaceuticals, and a significant increase in non-recurring revenue from license agreements. Despite a slight dip in oncology sales, strong R&D investments and strategic partnerships are driving PharmaMar’s financial performance.
For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.
